Aquestive Therapeutics share price logo

Aquestive Therapeutics

NASDAQ: AQST

Small Cap

$4.66

+0.17

(+3.67%)

as on

Aquestive Therapeutics Stock Performance

as on August 22, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $4.52
    $4.72
    downward going graph

    3.00%

    Downside

    1.29%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.93
    $7.55
    downward going graph

    37.12%

    Downside

    62.02%

    Upside

    downward going graph

Aquestive Therapeutics share price movements today

Previous Close
$4.50
Open
$4.54
Volume
2.3M
Market Cap
$533.4M
Day's Low - High
$4.52 - $4.72
52 Week Low - High
$2.93 - $7.55

Aquestive Therapeutics Historical Returns

1 Month Return
+ 3.16 %
3 Month Return
+ 1.92 %
1 Year Return
+ 3.41 %
3 Year Return
+ 144.25 %
5 Year Return
+ 13.94 %

Aquestive Therapeutics Stock Fundamentals & Key Indicators

Check Aquestive Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$533.4M

EPS (TTM)

-0.45

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-52.2M

Revenue (TTM)

54.1M

Profit Margin

-144.63%

Return On Equity TTM

0.00%

Aquestive Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aquestive Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$533.4M13.94%NA-144.63%NA
BUY$21.4B145.28%16.5886.14%NA
HOLD$18.6B9.88%-44.5634.83%2.9899999999999998%
BUY$42.7BNA19.814.55%126.42999999999999%
BUY$30.5B-64.28%12.4770.87%2.76%

Stock Returns calculator for Aquestive Therapeutics Stock including INR - Dollar returns

The Aquestive Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Aquestive Therapeutics investment value today

Current value as on today

₹1,24,260

Returns

₹24,260

(+24.26%)

Returns from Aquestive Therapeutics Stock

₹13,382 (+13.38%)

Dollar Impact

₹10,878 (+10.88%)

Analyst Recommendation on Aquestive Therapeutics Stock

Based on 7 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 7 analysts, 100% of analysts recommend a 'BUY' rating for Aquestive Therapeutics. Average target price of $9.22

Aquestive Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Aquestive Therapeutics.

What analysts predicted

49.46%UPSIDE

Target Price

$9.22

Current Price

$4.66

Analyzed by

7 Analysts

Target

$9.22

Aquestive Therapeutics target price $9.22, a slight upside of 49.46% compared to current price of $4.66. According to 7 analysts rating.

Indian Investors' Interest in Aquestive Therapeutics Stock

Search interest for Aquestive Therapeutics Stock has increased by 30% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:30% versus previous 30 day period

Aquestive Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
12
20
13
11
8
10
12
13
14
13
Gross Profit
7
15
9
7
5
5
8
7
10
9
Operating Income
-8
0
-8
-13
-19
-11
-11
-28
-4
-8
EBITDA
-8
1
-7
-12
-18
-9
-11
-27
-4
-18
Interest Expense
4
4
4
4
4
4
4
4
3
3
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-12
-2
-11
-17
-22
-13
-15
-31
-8
-22
Income Tax Expense
0
-
-
0
-
-
-
-
-
-
Net Income
-12
-2
-11
-17
-22
-13
-15
-31
-8
-22
Net Profit Margin
-106.43%
-13.66%
-84.99%
-143.72%
-262.96%
-135.44%
-120.61%
-244.79%
-55.77%
-165.45%

Aquestive Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
51
66
67
52
45
50
47
50
57
44
Gross Profit
35
47
46
32
32
35
28
29
39
27
Operating Income
0
0
-48
-52
-42
-34
-42
-15
-30
-69
EBITDA
2
2
-50
-53
-39
-45
-39
1
-26
-66
Interest Expense
6
7
7
9
13
22
12
7
16
17
Depreciation
-
3
3
2
3
2
2
1
0
0
Income Before Tax
-9
-8
-61
-66
-55
-70
-54
-7
-44
-83
Income Tax Expense
6
7
-4
6
9
19
5
0
0
-
Net Income
-9
-8
-61
-66
-55
-70
-54
-7
-44
-83
Net Profit Margin
-18.54%
-13.36%
-91.02%
-125.92%
-121.67%
-138.77%
-114.11%
-15.56%
-76.68%
-188.09%

Aquestive Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-2
-11
-17
-22
-13
-15
-31
-8
-22
Operating Cash Flow
-7
-11
-6
-23
-7
-12
-8
-14
-9
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
1
0
0
20
0
81
0
4
-2
Change in Cash
-5
-11
-6
-2
-8
68
-7
-10
-12

Aquestive Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-8
-61
-66
-55
-70
-54
-7
-44
-83
Operating Cash Flow
5
-12
-60
-45
-32
-9
-6
-35
-52
Investing Cash Flow
-2
-1
0
0
0
-2
0
0
0
Financing Cash Flow
4
58
49
28
30
11
3
83
102
Change in Cash
8
43
-11
-17
-3
0
-3
47
49

Mutual Funds that own Aquestive Therapeutics Stock

Check out the Mutual Funds with significant holdings in Aquestive Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.453848%
4333440
Federated Hermes MDT Series
1.495795%
1876729
Fidelity Salem Street Trust
0.900978%
1130430
Fidelity Concord Street Trust
0.728358%
913850
WASATCH FUNDS TRUST
0.682747%
856623

Global Institutional Holdings in Aquestive Therapeutics

Funds
Holdings
Vanguard
4.17%
iShares
3.62%
SPDR
1.09%
Joseph Edelman
0.6%
Simplify
0.22%

Aquestive Therapeutics News & Key Events

  • img

    Today's Timeline - 08 October

    Wed, 05:20 PM

    -

    Aquestive Therapeutics secures two new U.S. patents for Anaphylm, extending protection until 2037, potentially transforming anaphylaxis treatment.

Insights on Aquestive Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, AQST stock has moved up by 9.6%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AQST has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, United Therapeutics Corporation Common Stock has given 64.3% return, outperforming this stock by 47.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -8.05M → -22.86M (in $), with an average decrease of 183.8% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 14.44M → 13.81M (in $), with an average decrease of 4.3% per quarter

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
OrganisationAquestive Therapeutics
Headquarters30 Technology Drive, Warren, NJ, United States, 07059
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Daniel Barber
E-voting on sharesClick here to vote

Key Management of Aquestive Therapeutics

Name

Title

Mr. Peter E. Boyd

Senior Vice President of Information Technology & Chief People Officer

Ms. Sherry Korczynski

Chief Commercial Officer

Dr. Melina T. Cioffi Pharm.D.

Senior Vice President of Regulatory Affairs

Mr. Daniel Barber

CEO, President & Director

Mr. A. Ernest Toth Jr.

Senior VP & CFO

Ms. Lori J. Braender BSBA, Esq., J.D.

Corporate Secretary

Dr. Matthew William Davis M.D., R.Ph.

Chief Development Officer

Ms. Cassie Jung

Chief Operating Officer

Mr. Thomas A. Zalewski

Chief Legal Officer & Chief Compliance Officer

Dr. Matthew Greenhawt B.Sc., M.B.A., M.D.

Chief Medical Officer

FAQs

What is Aquestive Therapeutics share price today?

Aquestive Therapeutics share price today is $4.66 as on at the close of the market. Aquestive Therapeutics share today touched a day high of $4.72 and a low of $4.52.

What is the 52 week high and 52 week low for Aquestive Therapeutics share?

Aquestive Therapeutics share touched a 52 week high of $7.55 on and a 52 week low of $2.93 on . Aquestive Therapeutics stock price today i.e. is closed at $4.66,which is 38.28% down from its 52 week high and 59.04% up from its 52 week low.

What is Aquestive Therapeutics's market capitalisation today?

Aquestive Therapeutics market capitalisation is $0.00T as on .

How to invest in Aquestive Therapeutics Stock (AQST) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aquestive Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aquestive Therapeutics Shares that will get you 0.3219 shares as per Aquestive Therapeutics share price of $4.66 per share as on August 22, 2026 at 8:46 am IST.

What is the minimum amount required to buy Aquestive Therapeutics Stock (AQST) from India?

Indian investors can start investing in Aquestive Therapeutics (AQST) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in Aquestive Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Aquestive Therapeutics share’s latest price of $4.66 as on August 22, 2026 at 8:46 am IST, you will get 2.1459 shares of Aquestive Therapeutics. Learn more about fractional shares .

What are the returns that Aquestive Therapeutics has given to Indian investors in the last 5 years?

Aquestive Therapeutics stock has given 13.94% share price returns and 29.17% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?